Korean company Medison, best known as a maker of high-quality ultrasound equipment, will soon file for court receivership, according to Asian news services. The company is laboring
Korean company Medison, best known as a maker of high-quality ultrasound equipment, will soon file for court receivership, according to Asian news services. The company is laboring under a huge debt, reported Asia Pulse, and can no longer service its loans. Medison holds 247.2 billion won (US$185.4 million) in interest-bearing debt and has short-term liabilities maturing in 2003 exceeding 175 billion won (US$131.25 million). Company executives contacted creditors Jan. 29 about their decision to file for bankruptcy after missing a 4.4 billion won (US$3.3 million) loan payment, according to the Korea Times.
Founded in 1985, Medison quickly became an international icon for Korean prosperity, capturing a majority of the Korean marketplace for ultrasound and forging deals with international vendors to supply low-cost ultrasound equipment. The company also was a major promoter of real-time 3D ultrasound systems. Its demise appears to be due primarily to ill-considered ventures in Web-based businesses. The plunge in stock prices of companies in which Medison had invested borrowed funds began to destabilize the company more than a year ago, according to Asia Pulse. Medison posted 116 billion won in net losses in 2000 compared with 52.3 billion won in net profits the previous year. In a bid to remain solvent, Medison has been selling assets. Among these was its share in Kretztechnik, which GE purchased in October (SCAN 10/17/01). A statement released by Medison and its creditors, reported by Asia Pulse, said company executives are seeking corporate alliances and foreign investments.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.